Parkinson's Disease Therapeutic Market Revenue Is Expected To Cross $8 Billion By 2027
- FinancialNewsMedia.com News Commentary
PALM BEACH, Fla., May 5, 2021 /PRNewswire/ -- Parkinson's disease (PD) is a neurodegenerative disorder that affects predominately dopamine-producing ("dopaminergic") neurons in a specific area of the brain called substantia nigra. Symptoms generally develop slowly over years. The progression of symptoms is often a bit different from one person to another due to the diversity of the disease. According to the Parkinson's Foundation, people with PD may experience: tremors, mainly at rest and described as pill rolling tremor in hands, plus gait and balance problems. The cause remains largely unknown. Although there is no cure, treatment options vary and include medications and surgery. While Parkinson's itself is not fatal, disease complications can be serious. The Centers for Disease Control and Prevention (CDC) rated complications from PD as the 14th cause of death in the United States. Currently, a wide range of treatments is available for alleviating the symptoms of Parkinson's disease. According to the Parkinson's Disease Clinic and Research Center, University of California, US, gene therapy for Parkinson's disease has shown promising results in phase I studies. Phase II and III studies are currently under progress. A report from MarketsAndMarkets said that the Parkinson's disease treatment market is expected to reach USD 5.69 billion in 2022. Active healthcare stocks in the markets this week include